Access, Access, Access: Unmet Needs in Multiple Myeloma

Video

Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.

Transcript:

I think I’ve said it before a couple times: access, access, access. We need to figure out better ways to ensure every patient with myeloma has access to this new generation of cellular immunotherapies, either direct or indirect cellular immunotherapies. Right now, they’re grossly limited to academic centers with lots of [resources and] expertise because of the cytokine release syndrome and other aspects that make them a little more challenging to give [to patients], at least initially.

To effect real change in the community, or at least where multiple myeloma is being taken care of, we [have to] strive to translate these assets into more community-friendly therapeutics.

Transcript edited for clarity.

Recent Videos
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
Related Content
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

ONCOLOGY Staff
December 22nd 2025
Article

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

Higher MRD Negativity Rates Occur With Isa-RD in Older NDMM Population

Roman Fabbricatore
December 19th 2025
Article

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

Tim Cortese
December 15th 2025
Article

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

Tim Cortese
December 14th 2025
Article

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.